Navigation Links
York U autism-related study discovers how drug interferes with neuronal cell function
Date:7/7/2010

TORONTO, July 7, 2010 − A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.

It is an important finding because misoprostol is similar in structure to naturally-occurring prostaglandins, which are the key signaling molecules produced by fatty acids in the brain.

Past clinical studies have shown an association between misoprostol and severe neurodevelopmental defects including autism symptoms. Those studies looked at cases in Brazil in which women misused the drug early in pregnancy in unsuccessful attempts to terminate their pregnancies.

The York study examined mouse neuronal cells to discover how the drug actually interferes at a molecular level with prostaglandins, which are important for development and communication of cells in the brain.

"Early in the first trimester of pregnancy, neuronal cells reach out to communicate with one another," says Dorota Crawford, an assistant professor in the School of Kinesiology & Health Science in York's Faculty of Health. "Our study shows that misoprostol interferes with this process by increasing the level of calcium ions in neuronal extensions, which reduces the number and length of these extensions. It prevents the cells from communicating with each other. If changes in prostaglandin level alter the development or differentiation of cells, it may have a physiological impact."

Crawford and Javaneh Tamiji, who undertook the research for her master's thesis in the Neuroscience Graduate Diploma Program at York, co-authored a study published online in the journal Biochemical and Biophysical Research Communications: "Prostaglandin E2 and misoprostol induce neurite retraction in Neuro-2a cells."

There is no indication that women in Canada are misusing misoprostol to terminate pregnancies, and in fact the drug is used safely for other purposes such as treatment and prevention of gastrointestinal ulcers. However, during early neuronal development the drug misoprostol or other environmental factors such as infections or inflammations, which can also increase the level of prostaglandins, may interfere with normal brain function, says Crawford.

Crawford and Tamiji focused on the drug misoprostol because they had evidence from the clinical studies of the neurotoxic effects of the drug. They used misoprostol and the naturally occurring prostaglandins side by side in their study and found that both compounds produced the same effects on neuronal cell function.

The study shows that misoprostol interferes with the prostaglandin pathway in a dose-dependent manner in other words, the higher the dose, the greater the problems created.

"What that indicates to us is whether it is infection that will activate it, or whether it is the drug, it will cause the same effect," says Crawford.

Now that it has been shown that misoprostol affects interaction between cells, the next step will be to do animal studies on mice to examine the physiological impacts on particular parts of the brain, she says.

Crawford's lab is one of very few in the world that has adopted a multidisciplinary approach to the study of autism spectrum disorders, using molecular techniques to understand the link between causative biological factors (genes and environment) and the behavioural expression.


'/>"/>

Contact: Janice Walls
wallsj@yorku.ca
416-736-2100 x22101
York University
Source:Eurekalert

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. £2 million study to reveal workings of dementia genes
3. New study looks to define evangelicals and how they affect polling
4. CU-Boulder study suggests air quality regulations miss key pollutants
5. Researchers study acoustic communication in deep-sea fish
6. Study reveals homeowner perceptions in fire-prone areas
7. Researchers study how pistachios may improve heart health
8. Study: urban black bears live fast, die young
9. New study indicates link between weight gains during pregnancy and dieting history
10. Study reveals specific gene in adolescent men with delinquent peers
11. Sweat it out: UH study examines ability of sweat patches to monitor bone loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... & Investor Conference 2016, to be held February 8-9, ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, taking ... February 10-11, 2016. James Sapirstein , Chief ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... supplier of Semantic Graph Database technology has been recognized As “ Best in ... Corporate America Magazine. , “At Corporate America, it’s our priority to showcase prominent ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma ... company that applies its innovative TransCon technology to address ... at an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare ... Date:  , Wednesday, February 10, 2016 Time:  , ... www.ascendispharma.com . --> An audio webcast of ...
Breaking Biology Technology: